Headquartered in 2 Holzman Street, Rehovot Fiscal year ends December NASDAQ: KMDA kamada.com
Kamada Ltd. is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions, specializing in plasma-derived therapies. The company markets six FDA-approved specialty plasma-derived products — KEDRAB, GLASSIA, CYTOGAM, VARIZIG, WINRHO SDF, and HEPAGAM B — as well as KAMRAB and two equine-based anti-snake venom products. Kamada also distributes third-party pharmaceutical products in Israel and the MENA region through in-licensing partnerships, including biosimilar products. The company operates three FDA-approved plasma collection centers in Texas (Beaumont, Houston, and San Antonio) to support its growing demand for hyper-immune plasma and generate revenue from normal source plasma sales to other manufacturers. FIMI Opportunity Funds, a private equity firm in Israel, is the controlling shareholder with approximately 38% of outstanding ordinary shares. The company's strategy centers on organic growth of its proprietary portfolio, expansion of its distribution business, scaling plasma collection operations, and pursuing M&A and business development opportunities to enhance its product portfolio and commercial infrastructure. Updated
Expedia is sending shareholders about $55 million, at 48 cents a share, with the money arriving September 17. Prospect Capital, Solstice Advanced Materials, Kamada and Embecta are paying out today's group too. You need to own the shares today to get paid.
Kamada Ltd. is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions, specializing in plasma-derived therapies.
The Wall Street consensus 12-month price target for KMDA is $13.50.
